Introduction
============

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide, and represents a huge and growing economic and social burden.[@b1-copd-9-057] It is characterized by chronic inflammation and irreversible airflow obstruction, involving structural changes in the lung.[@b2-copd-9-057] Tobacco smoking is the most important risk factor for the development of COPD;[@b1-copd-9-057] however, not all patents with COPD have a history of smoking. As little as 50% of cases worldwide are related to smoking,[@b3-copd-9-057] and an estimated 10%--12% of individuals with COPD have never smoked.[@b4-copd-9-057] In other words, irreversible airflow obstruction also occurs in never smokers. Analysis of data from the international, population-based Burden of Obstructive Lung Disease (BOLD) study showed that 23.3% of subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2--4 COPD were never smokers.[@b4-copd-9-057] In the People's Republic of China, a large survey including 20,245 participants reported by Zhong et al[@b5-copd-9-057] in 2007 showed that the prevalence of COPD in those aged over 40 years was 8.2%, and 38.6% of those with COPD were non-smokers. In addition to tobacco smoking, COPD in the People's Republic of China is related to exposure to biomass and occupational dusts/gases/fumes, pulmonary problems in childhood, family history of respiratory disease, low educational level, poor socioeconomic status, aging, lower body mass index, poor ventilation in the kitchen, age, and genetic susceptibility.[@b6-copd-9-057],[@b7-copd-9-057]

While population-based studies have confirmed an incidence of COPD in non-smokers, few detailed studies have been performed in this population. For example, the classic study on the natural history of COPD by Fletcher et al[@b8-copd-9-057] excluded non-smokers and thus no information was provided for subjects without a history of smoking but with chronic irreversible airflow obstruction. Participants in clinical trials are also limited to smokers with COPD. Therefore, little is known about the clinical features of non-smokers with COPD or their differences and similarities compared with smokers who have COPD.

To address this issue, we undertook a retrospective observational study to investigate the differences in clinical presentation between non-smokers with COPD and smokers with COPD, including their respiratory symptoms, impaired lung function, and radiologic changes.

Materials and methods
=====================

This study was approved by the ethics committee of Zhongshan Hospital, Fudan University, where medical records were retrospectively reviewed.

Study population
----------------

Medical records for patients hospitalized at Zhongshan Hospital with a lung mass requiring further evaluation from January 2006 to December 2010 were retrospectively reviewed, and those with COPD were entered into this study. Respiratory physicians who had received standardized training were responsible for review of the records and data collection.

Participants who had had an exacerbation within 4 weeks of admission were excluded. Subjects with other lung diseases such as pulmonary tuberculosis, bronchiectasis, pneumosilicosis, interstitial lung disease, or pleural effusion, or a history of pneumonectomy were also excluded, as were patients who had airflow limitation due to abnormalities in the large airways.

Definitions
-----------

Lung function tests were performed routinely on admission for patients hospitalized with a lung mass before making a treatment plan. The lung function tests had been performed according to international guidelines using calibrated MS-PFT equipment (Jaeger Co, Würzburg, Germany). The diagnosis of COPD was according to the GOLD definition. Briefly, COPD was considered to be present if post-bronchodilator forced expiratory volume in the first second of expiration (FEV~1~)/forced vital capacity (FVC) ratio was less than 0.70.[@b9-copd-9-057] The grade of COPD based on FEV~1~ was classified as shown in [Table 1](#t1-copd-9-057){ref-type="table"}. Significant bronchodilator reversibility was defined as an increase in FEV~1~ or FVC of at least 12% and 200 mL, respectively, from baseline values. Non-smokers were defined as having \<5 pack-years of tobacco exposure; otherwise, the subjects were classified as smokers.

Data collection
---------------

The following information was collected: patient age, sex, smoking status (never smoker, ever smoker, current smoker), quantity of tobacco smoking exposure (pack-years), respiratory symptoms (chronic cough, chronic sputum, a history of/or concurrent wheezing), modified Medical Research Council dyspnea score, and comorbidity (hypertension, coronary heart disease, diabetes). Lung function test values and results of arterial blood gas analysis were collected. Computed tomographic scan images were retrieved from Picture Archiving and Communication Systems and examined independently by two radiologists, and emphysema was qualitatively recorded. The treatment given for COPD was also investigated and conformity with GOLD guidelines was evaluated. Two authors independently reviewed the medical records of all included cases. Any discrepancies were resolved by discussion with a referee to reach a final consensus.

Statistical analysis
--------------------

The data for continuous variables are expressed as the mean ± standard deviation, and bivariate analysis were performed using unpaired *t*-tests and Pearson correlation. For discrete variables and ranked variables, a Chi-squared (χ^2^) test and Spearman rank correlation analysis, respectively, were used. Multiple logistic regression was used to analyze differences in symptoms after adjusing for FEV~1~. All statistical analyses were performed using Statistical Package for the Social Sciences version 19.0 (SPSS Inc, Chicago, IL, USA). Values were considered to be statistically significant at *P*\<0.05.

Results
=======

Demographic data
----------------

A total of 643 patients with stable COPD during the study period were reviewed and 605 were included in the final analysis after excluding 38 cases with tuberculosis (n=33), bronchiectasis (n=2), pneumosilicosis (n=2), and pneumonectomy (n=1). The average age was 64.8±8.5 years, and 532 (87.9%) were males. In this cohort, the smoking prevalence in males was 70.3% (374/532), which was significantly higher than that in females (1.4%, 1/73, χ^2^=129.4, *P*\<0.001). Overall, among all the patients with COPD, 18.8%, 61.2%, 17.7%, and 2.3%, respectively, had mild (GOLD grade 1), moderate (grade 2), severe (grade 3), and very severe disease (grade 4).

The characteristics of COPD patients with and without a smoking history are summarized in [Table 2](#t2-copd-9-057){ref-type="table"}. Of all the 605 subjects, 375 (62.0%) had a history of smoking (three ex-smokers and 372 current smokers). Age and years with COPD, ie, years since diagnosis of COPD, were comparable between the two groups. Smokers with COPD were more likely to be men. Average tobacco exposure in smokers with COPD was about 45 pack-years.

Lung function parameters
------------------------

FEV~1~ and FVC were significantly lower in non-smokers with COPD than in smokers with COPD ([Table 3](#t3-copd-9-057){ref-type="table"}); however, the percentage of males was much lower in non-smokers than in smokers, which might account for these differences. After adjusting for sex and age, the differences in FEV~1~ and FVC between the two groups became nonsignificant, with *P*-values of 0.432 and 0.593, respectively. To avoid the confounding effect of the sex difference between non-smokers and smokers, percent predicted was used to analyze and present lung function parameters.

FEV~1~ percent predicted was higher in non-smokers with COPD than in smokers with COPD (*P*=0.021, [Table 3](#t3-copd-9-057){ref-type="table"}). Although there was no significant difference in distribution of COPD grades between the two groups ([Figure 1](#f1-copd-9-057){ref-type="fig"}), the quantity of tobacco smoked (pack-years) was negatively correlated with FEV~1~ percent predicted (*P*=0.009) and positively correlated with COPD grade (*P*=0.024, [Table 4](#t4-copd-9-057){ref-type="table"}). FEV~1~/FVC% was higher in non-smokers with COPD, and was negatively related to pack-years.

Vital capacity percent predicted and total lung capacity (TLC) percent predicted were both over 80%, and there was no difference between non-smokers with COPD and smokers with COPD. Therefore, the lower maximum ventilation volume percent predicted was another marker for poorer obstructive ventilatory function in smokers with COPD. PaCO~2~ levels were similar between the two groups.

Compared with smokers with COPD, non-smokers with COPD showed a lower residual volume (RV) percent predicted (*P*=0.044) and RV/TLC percent predicted (*P*=0.042). Inspired capacity (IC) percent predicted and IC/TLC% were higher for non-smokers with COPD, albeit not significantly so, but were negatively related to tobacco exposure (*P*=0.018 and *P*=0.003, respectively).

Diffusing capacity was also evaluated in our study. Diffusing capacity of lung (DLCO) percent predicted, serving as a predictor of pulmonary gas exchange, was higher for non-smokers with COPD than smokers with COPD (*P*=0.001), and was negatively correlated with pack-years (*P*\<0.001). Diffusing capacity divided by alveolar volume remained significant. PaO~2~ levels were similar between the two groups.

Respiratory symptoms
--------------------

Non-smokers with COPD had a significant lower prevalence of chronic cough and chronic sputum than smokers with COPD, independent of FEV~1~ ([Table 5](#t5-copd-9-057){ref-type="table"}). Tobacco exposure had a positive relationship with chronic cough and sputum, and the correlation remained significant after adjusting for FEV~1~ ([Table 6](#t6-copd-9-057){ref-type="table"}).

Non-smokers with COPD showed a trend towards less severe shortness of breath than smokers with COPD. As shown in [Table 5](#t5-copd-9-057){ref-type="table"}, smoking exposure was significantly correlated with mMRC score after adjusting for FEV~1~.

Asthma features
---------------

Some asthmatic patients develop fixed airflow limitation, and some COPD patients may have comorbid asthma. We thus looked into features of asthma, which was confirmed by a history of wheezing or documented asthma and airway reversibility. In our study population, no differences were found between non-smokers and smokers with COPD in this regard ([Table 7](#t7-copd-9-057){ref-type="table"}).

Emphysema on computed tomographic scan
--------------------------------------

The prevalence of emphysema in non-smokers with COPD (43/381, 11.3%) was significantly lower than that in smokers with COPD (9/225, 4.0%, *P*\<0.001).

Treatment according to GOLD guidelines
--------------------------------------

Less than 30% of the patients in this study were treated in accordance to GOLD recommendations. There was no difference in compliance with treatment between smokers with COPD (101/375, 26.9%) and non-smokers with COPD (64/230, 27.8%, *P*=0.851).

Comorbidities
-------------

The prevalence of comorbidities, including hypertension, diabetes, and coronary heart disease, was not significantly different between the two groups ([Table 8](#t8-copd-9-057){ref-type="table"}). One smoker with COPD had documented depression; however, no other psychologic disorders were recorded.

Discussion
==========

The current study provides a detailed description of impaired pulmonary function and symptoms of COPD in both never smokers and smokers. In spite of their comparable age and years since diagnosis, non-smokers with COPD showed less airflow limitation (higher levels of FEV~1~, FEV~1~/FVC%, and maximum ventilation volume) than smokers with COPD. The chronic inflammatory process induced by tobacco smoking promotes thickening and narrowing of the small conducting airways, as well as destruction of the parenchyma and reduced alveolar-bronchiolar attachments.[@b10-copd-9-057]--[@b15-copd-9-057] These additional changes could contribute to more severe expiratory airflow obstruction in smokers with COPD. Further, our findings that smokers with COPD tended to have more emphysema on radiologic examination and higher RV and poorer diffusing capacity on lung function testing are in line with evidence of extracellular matrix destruction induced by smoking.[@b11-copd-9-057],[@b12-copd-9-057],[@b15-copd-9-057],[@b16-copd-9-057]

Chronic cough and sputum production, associated with an abundance of mucus-producing elements in the large airways, are major symptoms of COPD.[@b1-copd-9-057] In our study, smokers with COPD reported significantly more chronic cough and phlegm than never smokers, which is consistent with the knowledge that tobacco smoke is responsible for goblet cell hyperplasia and chronic hypersecretion of mucus.[@b17-copd-9-057],[@b18-copd-9-057]

IC has been acknowledged to have a closer relationship with dyspnea than FEV~1~.[@b19-copd-9-057],[@b20-copd-9-057] Also, the mMRC score was negatively correlated with IC percent predicted (*P*\<0.001) and IC/TLC% (*P*=0.032) in the current study. Smoking exposure (pack-years) was consistently and significantly correlated with mMRC score, although most of participants did not report apparent dyspnea.

Smoking is a known cause of COPD, chronic bronchitis, and emphysema, and the risk increases with pack-years.[@b1-copd-9-057],[@b21-copd-9-057] The relationship between smoking and decline in FEV~1~ has been well established in the general population.[@b13-copd-9-057],[@b14-copd-9-057],[@b22-copd-9-057] However, in patients with confirmed COPD, few studies have compared such changes between smokers and non-smokers. In the population-based BOLD study,[@b4-copd-9-057] it was reported that never smokers made up 27.7% (523/1,889) of all COPD cases, and 70.8% of non-smokers with COPD were female, which was significantly higher than the 37.0% of female smokers with COPD. The same pattern was evident in our study, but we noted that the proportion of males was much higher due to the fact that the prevalence of smoking in females is considerably low in the People's Republic of China.[@b7-copd-9-057] In another study of 30 smokers and seven never smokers with very severe COPD and chronic respiratory failure, the authors reported less emphysema and more bronchiectasis in non-smokers with COPD but no differences in FEV~1~, IC, body mass index, mMRC score, SpO~2~ at rest, use of long-term oxygen therapy, or 6-minute walking distance between the two groups.[@b23-copd-9-057] The failure to detect a difference was at least partly due to the late stage of the disease, when smoking status would have limited impact on these measures. Another possible explanation is their small sample size. Our study included all of the disease categories as defined by GOLD spirometric criteria and had a larger sample size. We demonstrated more severe airflow limitation and gas exchange, worse emphysema, and a poorer symptomatic profile in COPD patients with a smoking history than those without. It is of note that the majority of our study population had mild or moderate COPD, indicating the benefits of quitting smoking in the early stages of COPD, ie, improvement in respiratory symptoms and prevention of an excessive decline in FEV~1~.[@b24-copd-9-057]--[@b27-copd-9-057]

It should be noted that the subjects in our study were hospitalized with a lung mass for further diagnosis and evaluation, and were likely to have had better lung function and fewer symptoms than a general COPD population. Subjects with GOLD grade 1 and grade 2 COPD comprised 18.8% (114/605) and 61.2% (370/605) of our cohort, respectively. In a large epidemiologic study in the People's Republic of China, the prevalence of mild, moderate, severe, and very severe COPD was 2.0%, 3.8%, 1.7%, and 0.4%, respectively, with an overall prevalence of COPD of 8.2%.[@b5-copd-9-057] Additionally, 44% of subjects with COPD had cough, 30% had sputum, and 49% had dyspnea in that study.[@b5-copd-9-057] In comparison, 13.1%, 11.3%, 1.8%, and 2.1% of the patients in our cohort had chronic cough, chronic sputum, obvious dyspnea (ie, mMRC score \>1), and wheezing, respectively. The study by Zhong et al[@b5-copd-9-057] involved seven cities from the east to west regions of the People's Republic of China and covered both urban and rural areas, and thus included a large variation in economic and health status, resulting in an imbalance in the prevalence of COPD and disease severity. In contrast, most of our patients were from the south-east urban area in and around Shanghai. This could also have contributed to the differences in severity and symptomatic patterns seen between the two studies.

Available epidemiologic data demonstrate that domestic biomass, fuel smoke, indoor air pollution, poor economic and social status, and existence of asthma might be important causes of COPD in never smokers, especially in women.[@b6-copd-9-057],[@b7-copd-9-057] A cluster sampling survey performed in populations aged over 40 years in Guangdong showed a significant relationship between COPD and exposure to biomass fuel for cooking.[@b28-copd-9-057] Another study from the Xuanwei District in Yunnan Province supports the association of indoor air pollution with COPD from another aspect. In that study, installation of chimneys on household coal stoves led to a substantial decrease in the incidence of COPD.[@b29-copd-9-057] A future cross-sectional and prospective cohort study should be performed to explore these risk factors and their impact on decline in lung function and worsening of respiratory symptoms.

There are several limitations to the current study that should be considered. First, it is a retrospective investigation, and data collection was based on medical records. Apart from smoking history, risk factors for COPD, such as occupation and indoor air pollution, were not analyzed because of incompleteness of data. Due to limitations in the clinical data that we could retrieve, we did not investigate non-smokers with COPD using comprehensive indices like the BODE index or updated GOLD disease category.[@b1-copd-9-057] Second, our study subjects were patients who were hospitalized with a lung mass, which might have an impact on lung function and symptoms, and led to bias. To avoid the influence of lung mass on the comparisons made in our study, those with pleural effusion or airflow limitation due to abnormalities in the large airways were carefully excluded. Third, 80% of our subjects had mild to moderate disease, and sample sizes for each level of disease severity were not balanced, which affected our power to detect modest differences. This would also lead to weak statistically significant correlations in our analysis. Fourth, this was a cross-sectional study, whereas longitudinal follow-up cohort research is required to look into whether differences in lung function decline and treatment responses exist between smokers and non-smokers with COPD.

Nevertheless, these limitations do not prevent the conclusion that non-smokers with COPD have less impairment of airflow limitation and gas exchange, and a lower prevalence of emphysema, chronic cough, and sputum compared with their smoking counterparts. Tobacco cessation is warranted in smokers with COPD.
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![Distribution of COPD grading for non-smokers with COPD and smokers with COPD.\
**Notes:** Grade 1, FEV~1~ %pred ≥80%; grade 2, 50% ≤FEV~1~ %pred \<80%; grade 3, 30%≤FEV~1~ %pred \<50%; grade 4, FEV~1~ %pred \<30% or FEV~1~ %pred \<50% plus chronic respiratory failure. Proportions of each grade in non-smokers with COPD versus smokers with COPD were as follows: grade 1, 20.4% versus 17.9%; grade 2, 63.5% versus 59.7%; grade 3, 14.8% versus 19.5%; and grade 4, 1.3% versus 2.9% (*P*=0.064).](copd-9-057Fig1){#f1-copd-9-057}

###### 

Definition and severity grading of COPD according to airflow obstruction

  Grade                        Post-bronchodilator spirometry
  ---------------------------- ---------------------------------------------------------------------------------------------
  Grade 1 (Mild COPD)          FEV~1~/FVC \<70%; FEV~1~ %pred ≥80%
  Grade 2 (Moderate COPD)      FEV~1~/FVC \<70%; 50% ≤FEV~1~ %pred \<80%
  Grade 3 (Severe COPD)        FEV~1~/FVC \<70%; 30% ≤FEV~1~ %pred \<50%
  Grade 4 (Very severe COPD)   FEV~1~/FVC \<70%; FEV~1~ %pred \<30% or FEV~1~ %pred \<50% plus chronic respiratory failure

**Notes:** Adapted by the author from the "Global Strategy for Diagnosis, Management and Prevention of COPD, 2013" Global initiative for Chronic Obstructive Lung Disease (GOLD), available from <http://www.goldcopd.org.1>

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; %pred, percentage of predicted.

###### 

Demographic data

                                  Non-smokers with COPD (n=230)   Smokers with COPD (n=375)   *P*-value
  ------------------------------- ------------------------------- --------------------------- -----------
  Age (years)                     65.1±9.2                        64.7±8.1                    0.574
  Male sex, n%                    158, 68.7%                      374, 99.7%                  \<0.001
  Tobacco exposure (pack-years)   0.07±0.52                       45.26±26.41                 \<0.001

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Comparisons of lung function and arterial blood gas values between non-smokers and smokers with COPD

                              Non-smoker COPD (n=230)   Smoker COPD (n=375)   *P*-value
  --------------------------- ------------------------- --------------------- -----------
  FEV~1~ (L)                  1.713±0.522               1.845±0.581           0.005
  FEV~1~ %pred                65.9±16.7                 62.6±17.2             0.021
  FEV~1~ %pred \<50%, n (%)   37 (16.1%)                84 (22.4%)            0.060
  FVC (L)                     2.738±0.739               2.994±0.754           \<0.001
  FVC %pred                   81.9±16.9                 80.4±18.2             0.316
  FEV~1~/FVC (%)              62.1±6.7                  60.8±7.6              0.037
  MVV %pred                   61.9±14.6                 58.5±13.9             0.004
  RV %pred                    101.9±28.9                107.0±31.2            0.044
  TLC %pred                   86.7±15.1                 87.0±14.0             0.808
  RV/TLC %pred                115.9±21.4                120.0±23.5            0.042
  IC %pred                    82.3±20.4                 80.8±19.1             0.369
  IC/TLC (%)                  42.1±9.1                  40.7±8.7              0.054
  DLCO %pred                  67.3±19.3                 61.9±18.8             0.001
  DLCO/VA (%)                 65.9±17.4                 61.2±18.6             0.002
  VC %pred                    81.7±16.6                 80.3±17.1             0.298
  pH value                    7.42±0.28                 7.42±0.29             0.734
  PaO~2~ (mmHg)               80.5±11.2                 81.4±11.7             0.332
  PaCO~2~ (mmHg)              40.7±3.9                  40.9±3.6              0.528

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in first second of expiration; FVC, forced vital capacity; MVV, maximum ventilation volume; RV, residual volume; TLC, total lung capacity; IC, inspired capacity; DLCO, diffusing capacity of lung; VA, alveolar volume; VC, vital capacity; %pred, percent predicted.

###### 

Correlation analysis of lung function parameters with tobacco exposure (pack-years)

                   Correlation (*r*)   *P*-value
  ---------------- ------------------- -----------
  FEV~1~ %pred     −0.107              0.009
  Grading          0.091               0.024
  FVC %pred        −0.072              0.078
  FEV~1~/FVC (%)   −0.082              0.044
  MVV %pred        −0.122              0.003
  RV %pred         0.068               0.097
  TLC %pred        −0.006              0.887
  RV/TLC %pred     0.075               0.067
  IC %pred         −0.097              0.018
  IC/TLC (%)       −0.121              0.003
  DLCO %pred       −0.183              \<0.001
  DLCO/VA (%)      −0.164              \<0.001
  VC %pred         −0.075              0.066

**Abbreviations:** FEV~1~, forced expiratory volume in first second of expiration; FVC, forced vital capacity; MVV, maximum ventilation volume; RV, residual volume; TLC, total lung capacity; IC, inspired capacity; DLCO, diffusing capacity of lung; VA, alveolar volume; VC, vital capacity; %pred, percent predicted.

###### 

Comparisons of chronic cough, sputum, and dyspnea between non-smokers with COPD and smokers with COPD

                          Non-smoker COPD (n=230)   Smoker COPD (n=375)   *P*-value   *P*-value adjusted for FEV~1~
  ----------------------- ------------------------- --------------------- ----------- -------------------------------
  Chronic cough, n (%)    19 (8.3%)                 60 (16%)              0.006       0.001
  Chronic sputum, n (%)   19 (8.3%)                 57 (15.2%)            0.016       0.002
  mMRC \>1, n (%)         3 (1.3%)                  8 (2.1%)              0.546       0.214

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in first second of expiration; mMRC, modified Medical Research Council dyspnea score.

###### 

Correlation analysis of respiratory symptoms with tobacco exposure (pack-years)

                   Correlation (*r*)   *P*-value   Correlation (*r*) adjusted for FEV~1~   Correlation *P*-value (adjusted for FEV~1~)
  ---------------- ------------------- ----------- --------------------------------------- ---------------------------------------------
  Chronic cough    0.110               0.007       0.097                                   0.017
  Chronic sputum   0.098               0.016       0.125                                   0.002
  mMRC score       0.044               0.285       0.082                                   0.045
  mMRC \>1         0.064               0.114       0.051                                   0.214

**Abbreviations:** FEV~1~, forced expiratory volume in first second of expiration; mMRC, modified Medical Research Council dyspnea score.

###### 

Comparisons of asthma features between non-smokers with COPD and smokers with COPD

                                                    Non-smoker COPD (n=230)   Smoker COPD (n=375)   *P*-value
  ------------------------------------------------- ------------------------- --------------------- -----------
  History of wheezing or documented asthma, n (%)   6 (2.6%)                  7 (1.9%)              0.572
  Airway reversibility, n (%)                       19 (15.3%)                32 (16.8%)            0.757

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Comparison of comorbidities between non-smokers with COPD and smokers with COPD

                                                                 Non-smoker COPD (n=230)   Smoker COPD (n=375)   *P*-value
  -------------------------------------------------------------- ------------------------- --------------------- -----------
  Hypertension, diabetes, and/or coronary heart disease, n (%)   59 (25.7%)                113 (30.1%)           0.265
  Hypertension                                                   50 (21.7%)                96 (25.6%)            0.328
  Coronary heart disease                                         4 (1.7%)                  11 (2.9%)             0.430
  Diabetes                                                       11 (4.8%)                 24 (6.4%)             0.476

**Abbreviation:** COPD, chronic obstructive pulmonary disease.
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